A narrative overview of active surveillance for clinically localised prostate cancer.

Published on Jul 20, 2020in Seminars in Oncology Nursing1.33
· DOI :10.1016/J.SONCN.2020.151045
Anthony Simon Bates2
Estimated H-index: 2
(ARI: Aberdeen Royal Infirmary),
Nikolaos Kostakopoulos3
Estimated H-index: 3
(ARI: Aberdeen Royal Infirmary)
+ 9 AuthorsThomas B. Lam42
Estimated H-index: 42
(Aberd.: University of Aberdeen)
Sources
Abstract
Background -Active surveillance (AS) is a strategy employed as an alternative to immediate standard active treatments for patients with low-risk localised prostate cancer (PCa). Active treatments such as radical prostatectomy and radiotherapy are associated with significant adverse effects which impair quality of life. The majority of patients with low-risk PCa undergo a slow and predictable course of cancer growth and do not require immediate curative treatment. AS provides a means to identify and monitor patients with low-risk PCa through regular PSA testing, imaging using MRI scans and regular repeat prostate biopsies. These measures enable the identification of progression, or increase in cancer extent or aggressiveness, which necessitates curative treatment. Alternatively, some patients may choose to leave AS to pursue curative interventions due to anxiety. The main benefit of AS is the avoidance of unnecessary radical treatments for patients at the early stages of the disease, hence avoiding over-treatment, whilst identifying those at risk of progression to be treated actively. The objective of this article is to provide a narrative summary of contemporary practice regarding AS based on a review of the available evidence base and clinical practice guidelines. Elements of discussion include the clinical effectiveness and harms of AS, what AS involves for healthcare professionals, and patient perspectives. The pitfalls and challenges for healthcare professionals are also discussed. Data sources We consulted international guidelines, collaborative studies and seminal prospective studies on AS in the management of clinically localised PCa. Conclusion AS is a feasible alternative to radical treatment options for low-risk PCa, primarily as a means of avoiding over-treatment, whilst identifying those who are at risk of disease progression for active treatment. There is emerging data demonstrating the long-term safety of AS as an oncological management strategy. Uncertainties remain regarding variation in definitions, criteria, thresholds and the most effective types of diagnostic interventions pertaining to patient selection, monitoring and reclassification. Efforts have been made to standardise the practice and conduct of AS. As data from high-quality prospective comparative studies mature, the practice of AS will continue to evolve. Implications for Nursing Practice The practice of AS involves a multi-disciplinary team of healthcare professionals consisting of nurses, urologists, oncologists, pathologists and radiologists. Nurses play a prominent role in managing AS programmes, and are closely involved in patient selection and recruitment, counselling, organising and administering diagnostic interventions including prostate biopsies, and ensuring patients' needs are being met throughout the duration of AS.
📖 Papers frequently viewed together
5 Citations
12 Citations
8 Citations
References38
Newest
#1Arveen Kalapara (Monash University)H-Index: 6
#1Arveen A. Kalapara (Monash University)H-Index: 2
Last. Sophie Bruinsma (EUR: Erasmus University Rotterdam)H-Index: 13
view all 81 authors...
Abstract Background Active surveillance (AS) enrolment criteria and follow-up schedules for low-risk prostate cancer vary between institutions. However, uncertainty remains about adherence to these protocols. Objective To determine adherence to institution-specific AS inclusion criteria and follow-up schedules within the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative. Design, setting, and participants We retrospectively assessed the data of 15 101 ...
13 CitationsSource
#1Thomas B. Lam (Aberd.: University of Aberdeen)H-Index: 42
#2Steven MacLennan (Aberd.: University of Aberdeen)H-Index: 22
Last. Nicolas MottetH-Index: 40
view all 69 authors...
Abstract Background There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective To develop consensus statements for all domains of DAT. Design, setting, and participants A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncolo...
58 CitationsSource
#1Anna Bill-Axelson (Uppsala University Hospital)H-Index: 27
#2Lars Holmberg (Uppsala University Hospital)H-Index: 103
Last. Jan-Erik Johansson (Uppsala University Hospital)H-Index: 60
view all 12 authors...
Abstract Background Radical prostatectomy reduces mortality among men with clinically detected localized prostate cancer, but evidence from randomized trials with long-term follow-up is sparse. Met...
165 CitationsSource
#1Richard J. Bryant (University of Oxford)H-Index: 18
#2Bob Yang (University of Oxford)H-Index: 2
Last. Simon Brewster (University of Oxford)H-Index: 21
view all 13 authors...
Objectives To determine whether replacement of protocol‐driven repeat prostate biopsy (PB) with multiparametric magnetic resonance imaging (mpMRI) +/‐ targeted repeat prostate biopsy (TB) in evaluating men on active surveillance (AS) for low‐volume low‐ to intermediate‐risk prostate cancer (PCa) altered the likelihood or time to treatment, or reduced the number of repeat biopsies required to trigger treatment. Patients and methods 445 patients underwent AS from 2010‐2016 at our institution with ...
15 CitationsSource
#1Netty Kinsella ('KCL': King's College London)H-Index: 4
#2Pär Stattin (Uppsala University)H-Index: 92
Last. Mieke Van Hemelrijck (KI: Karolinska Institutet)H-Index: 36
view all 8 authors...
Abstract Context Despite support for active surveillance (AS) as a first treatment choice for men with low-risk prostate cancer (PC), this strategy is largely underutilised. Objective To systematically review barriers and facilitators to selecting and adhering to AS for low-risk PC. Evidence acquisition We searched PsychINFO, PubMed, Medline 2000-now, Embase, CINAHL, and Cochrane Central databases between 2002 and 2017 using the Preferred Reporting Items for Systematic Review and Meta-analysis (...
36 CitationsSource
#1Melanie Evans (Monash University)H-Index: 5
#2Jeremy Millar (Monash University)H-Index: 29
Last. Sue M Evans (Alfred Hospital)H-Index: 32
view all 8 authors...
OBJECTIVE: To characterise the practice of active surveillance (AS) for men with low risk prostate cancer by examining the characteristics of those who commence AS, the rate of adherence to accepted AS follow-up protocols over 2 years, and factors associated with good adherence. Design, setting: Retrospective cohort study; analysis of data collected from 38 sites participating in the Prostate Cancer Outcomes Registry-Victoria. PARTICIPANTS: Men diagnosed with prostate cancer between August 2008 ...
13 CitationsSource
#1Sophie Bruinsma (EUR: Erasmus University Rotterdam)H-Index: 13
#2Liying Zhang (Sunnybrook Health Sciences Centre)H-Index: 26
Last. Mieke Van Hemelrijck ('KCL': King's College London)H-Index: 36
view all 7 authors...
OBJECTIVES: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low‐risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow‐up for AS in this unique global AS database. PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwid...
36 CitationsSource
#1Maria Komisarenko (Princess Margaret Cancer Centre)H-Index: 7
#2Lisa J Martin (Princess Margaret Cancer Centre)H-Index: 3
Last. Antonio Finelli (Princess Margaret Cancer Centre)H-Index: 53
view all 3 authors...
The primary goal of active surveillance (AS) is to prevent overtreatment by selecting patients with low-risk prostate cancer (PCa) and closely monitoring them so that definitive treatment can be offered when needed. With the increasing popularity of AS as a management strategy for men with localized PCa, it is important to understand all the contemporary guidelines and criteria that exist for AS and the differences among them. No single optimal management strategy for clinically localized, early...
19 CitationsSource
#1Veeru Kasivisvanathan (Royal Free London NHS Foundation Trust)H-Index: 17
#1Veeru Kasivisvanathan (Royal Free London NHS Foundation Trust)H-Index: 4
Last. Caroline M. Moore (London North West Healthcare NHS Trust)H-Index: 34
view all 41 authors...
Abstract Background Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography–guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited. Methods In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostate cancer who had not undergone biopsy previously to under...
964 CitationsSource
#1Steven MacLennan (Aberd.: University of Aberdeen)H-Index: 22
#2Paula R Williamson (Aberd.: University of Aberdeen)H-Index: 89
Last. Thomas B. Lam (Aberd.: University of Aberdeen)H-Index: 42
view all 11 authors...
Acknowledgements The authors wish to thank the following: Heather Bagley and Linda Pennet for their advice and assistance regarding patient and public involvement in research; Janice Forsyth and Sarah Murdoch for their assistance with logistics before and during the consensus meeting; Melanie Harper-Jones and Duncan Appelbe for their support in designing and managing the online Delphi survey and data; Vikki Entwistle for her advice during the protocol development stage; and Jane Blazeby and Liz ...
28 CitationsSource
Cited By1
Newest
#1Pamela Parker (University of Hull)
#2Maureen Twiddy (Hull York Medical School)H-Index: 14
Last. Matthew S. Simms (University of Hull)H-Index: 15
view all 5 authors...
BackgroundThe use of multiparametric magnetic resonance imaging (mpMRI) within active surveillance of prostate cancer programmes is identified by the UK National Institute for Health and Care Excel...
Source